We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Ends REMS for Diabetes Drug Rosiglitazone
The FDA is eliminating the risk evaluation and mitigation strategy for rosiglitazone-containing diabetes drugs, deciding enough is understood about its side effects.